FTC Seeks Contempt Sanctions Against Martin Shkreli Over Alleged Biotech Stock Trading

The Federal Trade Commission and seven states have asked a federal judge to hold Martin Shkreli in civil contempt, alleging that he repeatedly violated the lifetime ban that has barred him from the pharmaceutical industry since 2022. The request, filed Tuesday in federal court in Manhattan, does not create a new liability finding on its own. Instead, it asks the court to enforce an existing order after regulators said Shkreli ignored it.

According to the FTC’s October 13 announcement, the agency and its state co-plaintiffs allege that Shkreli publicly traded stocks of at least 60 pharmaceutical companies and broadcast his opinions about the business and management of many drugmakers after his release from prison in May 2022. Regulators say that conduct falls within the industry activity that a federal court permanently barred him from undertaking.

The distinction matters. The FTC is not announcing a fresh trial verdict or a new permanent injunction. It is alleging that Shkreli violated an injunction that was already in place, and it is asking the court to impose civil sanctions to force compliance. Until the judge rules, the accusations remain allegations in a contempt motion, not a final judicial finding that Shkreli has breached the order.

Even so, the filing is significant because the relief regulators are seeking goes beyond a symbolic reprimand. They want the court to require Shkreli to divest any pharmaceutical stocks he still owns, to pay a fine equal to his profits from pharmaceutical stock trading plus prejudgment interest, and to face escalating consequences for any future violations, including financial penalties and possible incarceration. That makes the filing both a legal enforcement step and a warning that the government intends to treat the 2022 ban as a live and meaningful restriction.

What the FTC says Shkreli did after the ban

The FTC’s public summary lays out a broad theory of noncompliance. Regulators say Shkreli did not merely make isolated comments about the drug industry from the sidelines. Instead, they allege he continued to involve himself directly in the sector by publicly trading pharmaceutical-industry stocks and by commenting online about pharmaceutical businesses and management teams. In the agency’s telling, those actions were not technical or accidental violations. They were repeated conduct that cut directly against the purpose of the lifetime ban.

The most concrete allegation in the FTC release is the claim that Shkreli traded the stocks of at least 60 pharmaceutical companies. The agency did not describe those trades in the press release as passive long-term holdings with no public engagement. Rather, it paired the trading allegation with claims that he also broadcast his views on companies online, which is central to why the contempt request has attracted attention beyond a narrow court-enforcement audience. The allegation is not simply that he owned shares. It is that he allegedly remained an active voice around the industry from which he had been banned.

That combination of trading and public commentary is especially relevant because the original court order was intended to remove Shkreli from the pharmaceutical business altogether. If the government can persuade the court that publicly trading and opining on drug-company management amounts to participating in the industry, then the contempt request becomes less about stretching an old order and more about enforcing it as written. If the court sees the conduct more narrowly, however, the dispute could turn on how far the injunction reaches into investment activity and public speech related to drugmakers.

For now, the government is clearly taking the broader view. Daniel Guarnera, director of the FTC’s Bureau of Competition, said in the agency release that when a court enters judgment, defendants must fulfill their obligations and that the FTC will not hesitate to enforce violations of court orders. The Commission vote authorizing staff to file the contempt action was 1-0, with Chairman Andrew N. Ferguson recused. Commissioner Mark Meador also issued a public statement.

The legal backdrop to the new contempt motion

The contempt request sits on top of a long-running antitrust case tied to Daraprim, a life-saving drug used to treat toxoplasmosis. The FTC’s Vyera Pharmaceuticals case page says the agency and a group of seven state enforcers sued in 2020, alleging that Shkreli and others orchestrated an anticompetitive scheme to preserve a monopoly over the drug. In January 2022, U.S. District Judge Denise Cote found that Shkreli had organized an illegal anticompetitive scheme and described his conduct as “egregious, deliberate, repetitive, long-running, and ultimately dangerous.”

That ruling carried extraordinary remedies. Judge Cote banned Shkreli for life from the pharmaceutical industry and ordered him to disgorge more than $64 million. In January 2024, the U.S. Court of Appeals for the Second Circuit affirmed the district court’s ruling, according to the FTC. So when the agency returned to court this week, it was doing so with an injunction that had already been imposed after trial and upheld on appeal.

That legal posture is important for two reasons. First, it gives the FTC a stronger footing than it would have if it were trying to enforce a novel or untested theory of relief. The lifetime ban already survived appellate review. Second, it shapes what the court will likely focus on next. The main question is no longer whether the underlying antitrust case justified severe remedies. The question is whether Shkreli’s alleged post-2022 conduct violated the order and, if so, what sanctions are appropriate to compel compliance.

The agency’s latest filing also underlines how unusual the original remedy was. A lifetime industry ban for an individual executive is a severe sanction, and the FTC has previously highlighted the case as a notable competition-enforcement outcome. That history helps explain why the agency is now pursuing contempt rather than treating the issue as a reputational or technical dispute. If regulators let a high-profile permanent ban go unenforced, the deterrent value of the underlying judgment would be undermined.

Why the case matters beyond Shkreli

The immediate stakes are personal for Shkreli, but the wider implications extend to antitrust enforcement, executive accountability and even how court orders are policed once the headlines fade. The FTC is effectively signaling that structural or behavioral remedies imposed on individuals are not self-executing. If regulators believe a defendant has resumed barred conduct, they will go back to court and ask for sharper tools.

That matters in competition policy because many enforcement actions end with forward-looking restrictions. Those restrictions only have force if agencies are willing to monitor conduct after the original case is over. In this instance, the contempt motion tells corporate executives that a high-profile injunction is not merely a press-release penalty. It is something regulators expect courts to enforce with financial consequences and, in extreme cases, the threat of incarceration.

The filing also matters because it touches on a gray area that courts increasingly face in the digital era: what counts as participation in an industry when a barred individual can trade securities, build an audience online and publicly influence discussion without formally running a company? Regulators appear to be arguing that the combination of public stock trading and public business commentary was enough to cross the line. How the court responds could help clarify the practical reach of industry bans in future cases.

For investors and market observers, the case is also a reminder that legal risk can attach not only to core antitrust conduct but to activity around the margins of a court order. The FTC’s request for a fine based on profits, with no offset for losses, suggests the agency wants sanctions that bite economically rather than merely restate the original judgment. That could become a meaningful precedent if courts increasingly face defendants accused of circumventing behavioral restrictions through trading or public messaging.

The broader story, then, is not simply that Martin Shkreli is back in court. It is that the FTC is testing how aggressively it can enforce one of the most prominent individual bans in modern antitrust practice. Whether the court agrees with the agency’s reading of Shkreli’s conduct will determine the immediate outcome. But the filing already sends a clear message: regulators want the pharmaceutical-industry ban imposed in 2022 to function as a real-world prohibition, not a historical headline that can be sidestepped once public attention moves on.